[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)",
    "summary": "Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider confidence, click for why VRTX stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=33e219893e5ff70d5426b444ee5aa22e2dd7a6608d34f9b1f1e8f72f4863156f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754930844,
      "headline": "Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)",
      "id": 136311902,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372801568/image_1372801568.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider confidence, click for why VRTX stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=33e219893e5ff70d5426b444ee5aa22e2dd7a6608d34f9b1f1e8f72f4863156f"
    }
  },
  {
    "ts": null,
    "headline": "3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates",
    "summary": "Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.",
    "url": "https://finnhub.io/api/news?id=e818c7ab040c6d6faecea6bdeee9326ce5f2a80ffa7e326f236e15f379470703",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754917800,
      "headline": "3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates",
      "id": 136295231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.",
      "url": "https://finnhub.io/api/news?id=e818c7ab040c6d6faecea6bdeee9326ce5f2a80ffa7e326f236e15f379470703"
    }
  },
  {
    "ts": null,
    "headline": "Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update",
    "summary": "Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25 Doses selected for KT-621 Phase 2b trials in AD and asthma, which are on track to initiate in 4Q25 and 1Q26, respectively KT-579 (IRF5) IND-enabling studies ongoing, with Phase 1 clinical trial expected to start in early",
    "url": "https://finnhub.io/api/news?id=625687d40babac811e1d6133527cf7fe829a60f3a693a058f8e269c5e3c4b285",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754910000,
      "headline": "Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update",
      "id": 136294379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25 Doses selected for KT-621 Phase 2b trials in AD and asthma, which are on track to initiate in 4Q25 and 1Q26, respectively KT-579 (IRF5) IND-enabling studies ongoing, with Phase 1 clinical trial expected to start in early",
      "url": "https://finnhub.io/api/news?id=625687d40babac811e1d6133527cf7fe829a60f3a693a058f8e269c5e3c4b285"
    }
  },
  {
    "ts": null,
    "headline": "Company News for Aug 11, 2025",
    "summary": "Companies In The News Are: GILD, TTD, TXRH, GEN.",
    "url": "https://finnhub.io/api/news?id=e4af0b6345128fddb87e459ba43b02a355dcea5d265d5a17c2056d73d5c2167b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754900100,
      "headline": "Company News for Aug 11, 2025",
      "id": 136294380,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Companies In The News Are: GILD, TTD, TXRH, GEN.",
      "url": "https://finnhub.io/api/news?id=e4af0b6345128fddb87e459ba43b02a355dcea5d265d5a17c2056d73d5c2167b"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.",
    "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
    "url": "https://finnhub.io/api/news?id=4a6b161a97e65ce1a4b104f66d2e62e059f1d1b958b21ca5e5226e3e45801fc7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754892000,
      "headline": "Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.",
      "id": 136294362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
      "url": "https://finnhub.io/api/news?id=4a6b161a97e65ce1a4b104f66d2e62e059f1d1b958b21ca5e5226e3e45801fc7"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside.",
    "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
    "url": "https://finnhub.io/api/news?id=93bac2fffa27ededc8bd751bb6ba8223840552fe849d03631f0fbd42d95bac1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754892000,
      "headline": "Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside.",
      "id": 136292433,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "While Celgene was absorbed by  Bristol Myers  in early 2019,  Gilead Sciences  has emerged as the enduring standout among the remaining trio.  Gilead has surged 59% and offers a healthy 2.6% dividend yield, while Amgen and Biogen have declined 11% and 16%, respectively.  Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction.",
      "url": "https://finnhub.io/api/news?id=93bac2fffa27ededc8bd751bb6ba8223840552fe849d03631f0fbd42d95bac1d"
    }
  }
]